Please ensure Javascript is enabled for purposes of website accessibility

This Stock Should Soar If the Stock Market Crashes This Summer

By Keith Speights - Jul 18, 2021 at 4:55AM

Key Points

  • Harry Dent Jr. predicts that a massive stock market crash will occur within three months.
  • There's a good case to be made that the rise of coronavirus variants could be the most likely culprit behind a near-term market meltdown.
  • One stock especially stands out as a potential beneficiary if this scenario occurs.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's the most likely winner benefiting from the most likely reason that an imminent crash might occur.

You might not have heard of Harry Dent Jr. He's an American author, economist, and investment firm founder who correctly predicted the Japanese economic downturn in 1989. He also forecast the dot.com bubble's collapse. 

Dent now believes that the stock market will crash within the next three months, with a good chance that it could happen before the end of July. And he doesn't think it will be a minor downturn. He recently stated in an interview with financial publication ThinkAdvisor that this "will be the biggest crash of our lifetime." 

There's no way to know if Dent's pessimistic outlook is warranted at this point. However, even if he's right, I don't think that every stock will plunge. There's at least one stock that should soar if the stock market crashes this summer.

Two blocks with down arrow and dollar sign, and hand adding third block with up arrow.

Image source: Getty Images.

Most likely culprit behind a crash

Dent thinks that the housing price bubble will pop and serve as the initial cause of a near-term stock market crash. I don't find that argument all that convincing. Interest rates remain near historic lows. The inventory of homes for sale is still well below the demand. Mortgage capital provider Freddie Mac expects the housing market to remain strong throughout this year.

If a market crash is on the way within the next few months as Dent predicts, my take is that there's a much more likely culprit -- the rise of coronavirus variants. This shouldn't be surprising considering that the coronavirus caused the most recent stock market crash a little over a year ago.

We're already seeing COVID-19 cases rise throughout the world, in large part because of the spread of the delta variant first identified in India. Just last week, several countries in Europe issued new travel restrictions as a result of concerns about this coronavirus variant.

One of the key drivers for the tremendous recovery for stocks after the sell-off in early 2020 was the expectation that the economic effect of the pandemic would be short-lived. Many investors have been banking on a widespread economic reopening. There's a possibility that new variants could dash those hopes and set the stage for another market meltdown.

The biggest beneficiary

My view is that vaccine stocks would likely take off if coronavirus variants cause a market crash within the next few months. After all, vaccines would be the best chance of beating the variants. I also believe that BioNTech (BNTX -1.30%) would be the biggest winner in the group.

Why BioNTech? For one thing, it's by far the smallest of the companies that currently have vaccines on the market. Catalysts usually generate bigger swings in stocks with smaller market caps than they do with those with larger market caps.

I think that it's important that BioNTech and its partner, Pfizer (PFE 0.22%), are already working on strategies to address the rise of the delta variant. The two companies believe that a third dose of their COVID-19 vaccine could provide more protection against this coronavirus strain. They also plan to begin clinical testing in August of a modified version of the vaccine that specifically targets the delta variant. 

There's also the matter of valuation. BioNTech is the cheapest of the leading vaccine stocks right now, based on forward earnings multiples. The biotech's shares trade at only 6.3 times expected earnings. I wouldn't expect that low valuation to last very long if fears about coronavirus variants increase so much that there's a huge market downturn.

A dent in the doomsaying

Now for a critical disclaimer: I don't think Dent's prediction of an imminent stock market crash will come true. It's not that there's no chance that he could be right; my view is just that it's unlikely that he will be.

I've already discussed why I don't agree with his take that the housing market bubble will precipitate a crash is on point. And while I do believe that the rise of coronavirus variants would be the most likely cause of a near-term market plunge, I nonetheless don't expect it to happen.

It's important to understand that the currently available COVID-19 vaccines are still highly effective at preventing severe disease -- even against the delta variant. The main problem, as I see it, with the rise in COVID-19 cases is that too few people have been fully vaccinated. However, enough individuals have been fully vaccinated that I don't expect a return of the lockdowns we saw last year. 

Also, with all due respect to Harry Dent, he's been wrong quite a bit in the past. As a case in point, he published a book titled The Great Depression Ahead in early 2009. In this book, he predicted a major economic depression that could last for a decade or more. History didn't treat that prediction kindly.  

Keith Speights owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioNTech SE Stock Quote
BioNTech SE
BNTX
$160.37 (-1.30%) $-2.11
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.86 (0.22%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
403%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.